In this respect, the FoundationOne® CDx test (a large-scale genomic profiling assay targeting up to 324 genes) was approved by FDA as a companion diagnostic test for pemigatinib therapy in CCA patients with FGFR2 fusions or other rearrangements [112]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.